Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway
Chemical Communications2010Vol. 46(29), pp. 5340–5340
Citations Over Time
Abstract
The mevalonate pathway is an important drug target for the treatment of cancer and cardiovascular disease. We synthesized and studied a new type of nitrogen-containing bisphosphonate analogs and developed a sensitive end point assay method for enzyme FPPS, which was used for inhibitor screening. One potent FPPS inhibitor was discovered, and the structure-activity relationship of bisphosphonates for the enzyme inactivation was studied.
Related Papers
- → Functional Characterization of the Xanthophyllomyces dendrorhous Farnesyl Pyrophosphate Synthase and Geranylgeranyl Pyrophosphate Synthase Encoding Genes That Are Involved in the Synthesis of Isoprenoid Precursors(2014)37 cited
- → Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells(2011)18 cited
- → Direct and indirect antitumor activity of zoledronic acid(2009)1 cited
- → Potential mechanisms for the anti-myeloma properties of bisphosphonates(2005)2 cited
- → Manipulation of the mevalonate pathway in glial‐derived cells(2008)